Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
- Status
- CompletedResults none
- Why it is watched
- population of special interest (non-obese / healthy / non-diabetic)
- Who it enrolls
- age 30 Years to 75 Years; healthy volunteers accepted; excludes diabetes; BMI ≥27 required; conditions: Pulmonary Disease, Chronic Obstructive
- Interventions
- Liraglutide; Placebo
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Phase and size
- Phase 4 · 40 participants
- Dates
- Start 2018-01-01
Primary completion 2020-05-31 - Sponsor
- Claus Bogh Juhl (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Transition Dyspnea Index (TDI)40 weeks
Published results in the collection
- FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patientsRandomized trial · 2024 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
02Eligibility
Who can take part
Inclusion Criteria: 1. Informed consent obtained before any trial-related activities 2. COPD as defined by FEV1/FVC\<70% after maximal broncho-dilatation and in accordance with the Gold guidelines 2017 (25) 3. Previous smoking of ≥ 20 pack-years 4. Overweight defined as BMI \> 27 kg/m2 5. Age 30 - 75 years 6. Women of childbearing potential must use a safe anti-contraceptive method Exclusion Criteria: 1. Chronic treatment with systemic steroids (inhalation steroids allowed) 2. Current smokers 3. Diabetes mellitus type 1 and type 2 as defined by current or previous treatment with antidiabetic medications of any kind or HbA1c ≥ 48mmol/mol 4. Severe hepatic disease (Alanine transferase \> 3 x UNL) 5. Severe impaired renal function (eGFR \< 30ml/min) 6. Congestive heart disease New York Heart Association (NYHA) class 3-4 7. History of acute or chronic pancreatitis 8. History of cholecystitis or cholecystolithiasis 9. Pregnant or breastfeeding women 10. Known bronchial asthma or interstitial lung disease 11. Family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma 12. Large goiter or plasma-calcitonin \> 50ng/ml
03Change log
Registry changes
No changes recorded since the trial was added.